The abundance of publications in the first three months of 2020 indicates the intensive scientific effort to address both molecular mechanisms and therapeutic routes for treating COVID-19. A specific RT-PCR-based test has been developed that is in use for clinical diagnoses. The virus genome has been sequenced that allowed the development of diagnostic tests and research into vaccines and therapeutics. The principal feature of the severe disease is acute onset of hypoxemic respiratory failure with bilateral infiltrates. People with COVID-19 show symptoms of fever, cough, muscle aches, headache, and diarrhea. Human to human transmission occurs through droplets, contact, and fomites. On January 30, 2020, the World Health Organization officially declared the COVID-19 epidemic as a public health emergency of international concern. The epicenter of the COVID-19 coronavirus outbreak was the central Chinese city of Wuhan, from where it spread globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the genus Betacoronavirus of the Coronaviridae family and is identified as the pathogen of Coronavirus disease 2019 (COVID-19). We advocate this vaccine must be synthesized and tested urgently as a public health priority. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. However, its efficacy and potency have to be evaluated and validated. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. Thus, for controlling COVID-19, vaccines may be a better option than drugs. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |